Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sosei Group ( (JP:4565) ) has provided an update.
Nxera Pharma has entered an out-licensing and investment agreement with a newly formed company to advance a non-core, preclinical GPCR-targeted program discovered using its NxWave platform. The deal grants NewCo an exclusive global license outside Japan and certain Asia-Pacific territories, while Nxera retains regional rights and a significant minority equity stake.
Under the terms, Nxera could receive up to US$275 million in development and commercial milestone payments plus tiered royalties, creating a potential new revenue stream and value upside. The move represents Nxera’s second use of an asset spin-out model, allowing dedicated external capital and leadership to drive the program toward global clinical trials, while reinforcing its strategy of monetizing non-core assets and strengthening its position in GPCR drug discovery.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen1400.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for patients with unmet needs in Japan and globally. It combines an agile commercial business in Japan, where it has several launched products, with an extensive pipeline powered by its NxWave GPCR structure-based drug discovery platform, operating from hubs in Japan, the U.K., Switzerland and South Korea.
YTD Price Performance: 41.11%
Average Trading Volume: 1,027,583
Technical Sentiment Signal: Hold
Current Market Cap: Yen107.1B
See more data about 4565 stock on TipRanks’ Stock Analysis page.